Phone: (707) 546-5553
Email Us
1140 Sonoma Avenue 1-A
Santa Rosa, CA 95405

Monthly Archives: July 2015

Dr. Michael Lazar Named Medical Director of the SonaCare HIFU Pilot Project in Puerto Vallarta

Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU, a medical procedure that applies high-intensity focused ultrasound energy to locally heat and destroy diseased or damaged tissue with prostate cancer through ablation. Dr. Lazar is working closely with SonaCare to bring this innovative service to Americans with this disease. Leading Santa Rosa, California, Urologist Dr. Michael Lazar, has been named Medical Director of the High Intensity Focused Ultrasound (HIFU) project currently underway at a well-equipped medical facility in Puerto Valarta, Mexico. This procedure involves the implementation of a new technology using sound waves to destroy cancer cells in the male prostate gland.

This project is sponsored by SonaCare Medical, LLC, developers of minimally-invasive HIFU technologies designed to significantly improve the quality of life for prostate cancer patients using focused ultrasound energy waves emitted from the firm’s Sonablate® 500 transrectal probe to destroy cancer cells without conventional surgery.

SonaCare’s Sonablate® 500HIFU Ablation Software™ utilizing T3 Technology™ enables the operator to target ablation zones with sophisticated planning and localization tools, treat disease with pin point accuracy while sparing untargeted tissue and track with advanced real-time ultrasound imaging.

Dr. Lazar has been a pioneer in the application of HIFU by working closely with SonaCare physicians and engineers in the development of this new technique. He has been treating patients with successful HIFU procedures with minimal side effects since April 2007.

“In the past, the entire prostate gland was removed surgically or irradiated causing issues associated with incontinence, erectile dysfunction (ED) and weeks of recovery,” says Dr. Lazar. “Today we can cure the cancer by treating the whole gland, or focally in the region of the cancer only, in just a few hours without blood loss and minimal side effects. This is a real game changer. Virtually all patients can be up and walking out of the hospital the same day to resume normal activities with little or no pain.”

Dr. Lazar said that cancer can now be detected in very early stages based on PSA blood testing along with MRI and ultrasound scans and a biopsy. This may allow treating only the areas with cancer cells using HIFU rather than excising the whole gland with a scalpel. Another factor to consider is that many cancers of the prostate progress slowly, so there is less reason to destroy the entire prostate just to address localized cancer that has not spread throughout the gland, a significant factor when it comes to maintaining erectile function and urine flow through the urethra following a full oblation (removal) procedure.

While HIFU is pending FDA approval for general use in the United States, SonaCare Medical is currently conducting a clinical trial in the U.S. and Canada to determine the safety and efficacy of a minimally invasive prostate cancer treatment using HIFU with the Sonablate® 500. The trial is for patients who have recurrent prostate cancer after receiving a previous treatment with external beam radiation therapy. To be eligible to be considered for the U.S. recurrent trials, candidates must:

• Have been treated with external beam radiation therapy two or more years prior;
• Have low-risk, organ-confined recurrent prostate cancer T1c or T2a;
• Be between the ages of 40 and 85;
• Have a PSA level between 0.5ng/mL and 10ng/mL;
• Have a recent (within six months) prostate biopsy that is positive for cancer.

There is no cost to enroll in the study, nor does it require health insurance. For more information call 877.605.HIFU.

For more information about Dr. Michael Lazar visit this page, or call (707) 546-5553. His office is located at 1140 Sonoma Ave #1A, Santa Rosa, CA 95405.

By | July 23rd, 2015|Dr. Michael Lazar, HIFU, News, Prostate Cancer|0 Comments

“Because of HIFU and the compassionate care I received, I now have a new lease on life …”

Barry Roach, 74, had physical exams and PSA tests performed by his primary doctor every year starting at age 65. His PSA numbers were steady in the 1.0-­to-­3.0 range. Even at age 75, a PSA of 6.0 is considered OK.  “In 2012 my PSA increased to 3.5, then 5.0 in 2013, and 5.4 in 2014, reaching 6.0 by June. A 1.0 or more rise within a year signals a need for action. I read reports from Johns Hopkins devoted to prostate cancer and different procedures. I scheduled an appointment with a urologist who recommended a biopsy. I found an article about proton beam therapy. While there are no side effects, treatments take 60 to 90 days, and the nearest facility was in SoCal. Then I came across HIFU on Google.” While HIFU has been used successfully for decades in Canada, Europe and Asia, it is not yet FDA approved as a accepted treatment in the U.S. in most cases. “I read a news story about Dr. Lazar’s leadership using High Intensity Focused Ultrasound therapy and went to see him. He performed a biopsy and used an ultrasound probe to check my prostate’s size, appearance and symmetry. Twelve samples were taken. The prostate appeared normal. However, three cores had cancer cells -­-­ more than two is a red flag. My Gleason score was 4 + 4, for a combined score of 8. If 6 or less, it would not have been a major concern, 7 is in between, and 8-­to-­10 means the cancer is aggressive.
Lazar bottom half

By | July 2nd, 2015|Alternative Treatment for Prostate Cancer, Dr. Michael Lazar, HIFU, Prostate Cancer, Testimonials, Uncategorized|Comments Off on “Because of HIFU and the compassionate care I received, I now have a new lease on life …”